Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development

Ting Hsuan Chen; Wen Chun Liu; I. Chen Chen; Chia Chyi Liu; Ming Hsi Huang; Jia Tsrong Jan; Suh Chin Wu

doi:10.1016/j.vaccine.2019.02.040

Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development

Ting Hsuan Chen, Wen Chun Liu, I. Chen Chen, Chia Chyi Liu, Ming Hsi Huang, Jia Tsrong Jan, Suh Chin Wu

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

The novel H7N9 avian influenza A virus has caused human infections in China since 2013; some isolates from the fifth wave of infections have emerged as highly pathogenic avian influenza viruses. Recombinant hemagglutinin proteins of H7N9 viruses can be rapidly and efficiently produced with low-level biocontainment facilities. In this study, recombinant H7 antigen was obtained from engineered stable clones of Chinese Hamster Ovary (CHO) cells for subsequent large-scale production. The stable CHO cell clones were also adapted to grow in serum-free suspension cultures. To improve the immunogenicity of the recombinant H7 antigens, we evaluated the use of a novel combination adjuvant of PELC and CpG (PELC/CpG) to augment the anti-H7N9 immune responses in mice. We compared the effects with other adjuvants such as alum, AddaVax (MF59-like), and several Toll-like receptor ligands such as R848, CpG, and poly (I:C). With the PELC/CpG combination adjuvant, CHO cell-expressed rH7 antigens containing terminally sialylated complex type N-glycans were able to induce high titers of neutralizing antibodies in sera and conferred protection following live virus challenges. These data indicate that the CHO cell-expressed recombinant H7 antigens and a PELC/CpG combination adjuvant can be used for H7N9 subunit vaccine development.

Original language	English
Pages (from-to)	6933-6941
Number of pages	9
Journal	Vaccine
Volume	37
Issue number	47
DOIs	https://doi.org/10.1016/j.vaccine.2019.02.040
State	Published - 8 Nov 2019
Externally published	Yes

Keywords

CHO cells
H7N9 vaccine
Hemagglutinin
PELC/CpG adjuvant

Access to Document

10.1016/j.vaccine.2019.02.040

Cite this

@article{4ef2533140c94fa09b0d9a53467df6a7,

title = "Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development",

abstract = "The novel H7N9 avian influenza A virus has caused human infections in China since 2013; some isolates from the fifth wave of infections have emerged as highly pathogenic avian influenza viruses. Recombinant hemagglutinin proteins of H7N9 viruses can be rapidly and efficiently produced with low-level biocontainment facilities. In this study, recombinant H7 antigen was obtained from engineered stable clones of Chinese Hamster Ovary (CHO) cells for subsequent large-scale production. The stable CHO cell clones were also adapted to grow in serum-free suspension cultures. To improve the immunogenicity of the recombinant H7 antigens, we evaluated the use of a novel combination adjuvant of PELC and CpG (PELC/CpG) to augment the anti-H7N9 immune responses in mice. We compared the effects with other adjuvants such as alum, AddaVax (MF59-like), and several Toll-like receptor ligands such as R848, CpG, and poly (I:C). With the PELC/CpG combination adjuvant, CHO cell-expressed rH7 antigens containing terminally sialylated complex type N-glycans were able to induce high titers of neutralizing antibodies in sera and conferred protection following live virus challenges. These data indicate that the CHO cell-expressed recombinant H7 antigens and a PELC/CpG combination adjuvant can be used for H7N9 subunit vaccine development.",

keywords = "CHO cells, H7N9 vaccine, Hemagglutinin, PELC/CpG adjuvant",

author = "Chen, {Ting Hsuan} and Liu, {Wen Chun} and Chen, {I. Chen} and Liu, {Chia Chyi} and Huang, {Ming Hsi} and Jan, {Jia Tsrong} and Wu, {Suh Chin}",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2019",

month = nov,

day = "8",

doi = "10.1016/j.vaccine.2019.02.040",

language = "English",

volume = "37",

pages = "6933--6941",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "47",

}

TY - JOUR

T1 - Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development

AU - Chen, Ting Hsuan

AU - Liu, Wen Chun

AU - Chen, I. Chen

AU - Liu, Chia Chyi

AU - Huang, Ming Hsi

AU - Jan, Jia Tsrong

AU - Wu, Suh Chin

PY - 2019/11/8

Y1 - 2019/11/8

N2 - The novel H7N9 avian influenza A virus has caused human infections in China since 2013; some isolates from the fifth wave of infections have emerged as highly pathogenic avian influenza viruses. Recombinant hemagglutinin proteins of H7N9 viruses can be rapidly and efficiently produced with low-level biocontainment facilities. In this study, recombinant H7 antigen was obtained from engineered stable clones of Chinese Hamster Ovary (CHO) cells for subsequent large-scale production. The stable CHO cell clones were also adapted to grow in serum-free suspension cultures. To improve the immunogenicity of the recombinant H7 antigens, we evaluated the use of a novel combination adjuvant of PELC and CpG (PELC/CpG) to augment the anti-H7N9 immune responses in mice. We compared the effects with other adjuvants such as alum, AddaVax (MF59-like), and several Toll-like receptor ligands such as R848, CpG, and poly (I:C). With the PELC/CpG combination adjuvant, CHO cell-expressed rH7 antigens containing terminally sialylated complex type N-glycans were able to induce high titers of neutralizing antibodies in sera and conferred protection following live virus challenges. These data indicate that the CHO cell-expressed recombinant H7 antigens and a PELC/CpG combination adjuvant can be used for H7N9 subunit vaccine development.

AB - The novel H7N9 avian influenza A virus has caused human infections in China since 2013; some isolates from the fifth wave of infections have emerged as highly pathogenic avian influenza viruses. Recombinant hemagglutinin proteins of H7N9 viruses can be rapidly and efficiently produced with low-level biocontainment facilities. In this study, recombinant H7 antigen was obtained from engineered stable clones of Chinese Hamster Ovary (CHO) cells for subsequent large-scale production. The stable CHO cell clones were also adapted to grow in serum-free suspension cultures. To improve the immunogenicity of the recombinant H7 antigens, we evaluated the use of a novel combination adjuvant of PELC and CpG (PELC/CpG) to augment the anti-H7N9 immune responses in mice. We compared the effects with other adjuvants such as alum, AddaVax (MF59-like), and several Toll-like receptor ligands such as R848, CpG, and poly (I:C). With the PELC/CpG combination adjuvant, CHO cell-expressed rH7 antigens containing terminally sialylated complex type N-glycans were able to induce high titers of neutralizing antibodies in sera and conferred protection following live virus challenges. These data indicate that the CHO cell-expressed recombinant H7 antigens and a PELC/CpG combination adjuvant can be used for H7N9 subunit vaccine development.

KW - CHO cells

KW - H7N9 vaccine

KW - Hemagglutinin

KW - PELC/CpG adjuvant

UR - http://www.scopus.com/inward/record.url?scp=85063385062&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.02.040

DO - 10.1016/j.vaccine.2019.02.040

M3 - Article

C2 - 31383491

AN - SCOPUS:85063385062

SN - 0264-410X

VL - 37

SP - 6933

EP - 6941

JO - Vaccine

JF - Vaccine

IS - 47

ER -

Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development

Abstract

Keywords

Access to Document

Fingerprint

Cite this